Drugs.com New Drug ApprovalsOriginal article
U.S. FDA Approves Update to the Label for Winrevair (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial
RegulatoryapprovedWinrevairPositive
AI Analysis
Summary
Merck announced FDA approval of a label update for Winrevair (sotatercept-csrk) incorporating Phase 3 HYPERION trial data. This regulatory approval expands the clinical evidence supporting the drug's use.
Clinical Trial Data
Phase
Phase 3
Outcome Details
FDA approved update to U.S. product label for Winrevair to include Phase 3 HYPERION trial data
Importance:6/10
Sentiment:
0.70
FDA approvallabel updatePhase 3 dataWinrevairregulatory
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on September 22, 2026 8:09 PM